Artico M, Di Santo R, Costi R, Massa S, Retico A, Artico M, Apuzzo G, Simonetti G, Strippoli V
Dipartimento di Studi Farmaceutici, Facoltà di Farmacia, Università di Roma La Sapienza, Italy.
J Med Chem. 1995 Oct 13;38(21):4223-33. doi: 10.1021/jm00021a011.
A new class of potent antifungal agents, namely, 3-aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]-pyrroles, is described. These compounds are related to bifonazole and pyrrolnitrin, two compounds belonging to the class of antimycotic drugs. The synthesis of the title pyrroles has been performed starting from 1,3-diaryl-2-propen-1-ones, which were reacted with tosylmethyl isocyanide to give 3-aroyl-4-arylpyrroles. Reduction of the resulting compounds by lithium aluminum hydride furnished the related alcohols, which were treated with 1,1'-carbonyldimidazole to afford the required imidazole derivatives. Forty-four new pyrroles which incorporate an (arylmethyl)imidazole moiety in the 3-arylpyrrole structure were prepared by the above procedure and tested in vitro against Candida albicans and Candida spp. Among test compounds, 10 were found to be highly active against C. albicans. The most active derivative (27) was twice as potent (MIC90) as bifonazole, and its activity was 4 times greater than those of miconazole and ketoconazole. The other nine compounds showed antifungal activity of the same order of that of bifonazole and were ca. 2 times as active as miconazole and ketoconazole. Derivatives 21 and 27 tested in vivo against C. albicans A170 were shown to be highly effective in rabbit skin candidosis. Pharmacological studies on compounds 27 and other related pyrroles (19, 35, 36, 38, 39, and 49) are in progress to select one of them as a potential candidate for clinical experiments.
描述了一类新型的强效抗真菌剂,即3-芳基-4-[α-(1H-咪唑-1-基)芳基甲基]吡咯。这些化合物与联苯苄唑和硝吡咯菌素有关,这两种化合物属于抗真菌药物类别。标题吡咯的合成是从1,3-二芳基-2-丙烯-1-酮开始进行的,该化合物与甲苯磺酰甲基异氰化物反应生成3-芳酰基-4-芳基吡咯。用氢化铝锂还原所得化合物得到相关醇类,然后用1,1'-羰基二咪唑处理以得到所需的咪唑衍生物。通过上述方法制备了44种在3-芳基吡咯结构中含有(芳基甲基)咪唑部分的新型吡咯,并对白色念珠菌和念珠菌属进行了体外测试。在测试化合物中,发现10种对白色念珠菌具有高活性。活性最高的衍生物(27)的效力(MIC90)是联苯苄唑的两倍,其活性比咪康唑和酮康唑高4倍。其他9种化合物显示出与联苯苄唑相同级别的抗真菌活性,并且活性约为咪康唑和酮康唑的2倍。在体内对白色念珠菌A170进行测试的衍生物21和27在兔皮肤念珠菌病中显示出高效性。正在对化合物27和其他相关吡咯(19、35、36、38、39和49)进行药理研究,以选择其中一种作为临床实验的潜在候选药物。